Standout Papers

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplati... 2004 2026 2011 2018 1.5k
  1. Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2004)
    David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 25 from Science/Nature 80 standout
Sub-graph 1 of 16

Citing Papers

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Tumour vasculature at single-cell resolution
2024 StandoutNature
2 intermediate papers

Works of Jacques Gaudreault being referenced

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data
2001

Author Peers

Author Last Decade Papers Cites
Jacques Gaudreault 1167 1336 1173 36 3.2k
Lisa A. Damico 1651 1215 1100 33 3.7k
Dana D. Hu‐Lowe 1734 997 788 33 3.0k
Frank A. Scappaticci 1193 1382 842 38 2.8k
Nicholas Papadopoulos 1688 554 307 53 3.5k
Michael N. Needle 1024 2431 1804 71 5.1k
Michael Loughnan 1175 589 248 23 2.6k
David R. Shalinsky 2254 1679 1000 51 4.3k
Francesco Hofmann 4152 1433 891 55 5.8k
Annette Hogg 588 878 1100 50 3.1k
R. Mass 1007 2431 1177 43 3.4k

All Works

Loading papers...

Rankless by CCL
2026